- Home
- ADCT vs IMMP Comparison
ADCT vs IMMP Comparison
Compare ADCT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- IMMP
- Stock Information
- Founded
- ADCT 2011
- IMMP 1987
- Country
- ADCT Switzerland
- IMMP Australia
- Employees
- ADCT N/A
- IMMP N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- ADCT Health Care
- IMMP Health Care
- Exchange
- ADCT Nasdaq
- IMMP Nasdaq
- Market Cap
- ADCT 285.2M
- IMMP 264.7M
- IPO Year
- ADCT 2020
- IMMP N/A
- Fundamental
- Price
- ADCT $1.98
- IMMP $1.85
- Analyst Decision
- ADCT Strong Buy
- IMMP Buy
- Analyst Count
- ADCT 5
- IMMP 2
- Target Price
- ADCT $7.33
- IMMP $8.50
- AVG Volume (30 Days)
- ADCT 417.8K
- IMMP 115.6K
- Earning Date
- ADCT 11-07-2024
- IMMP 11-26-2024
- Dividend Yield
- ADCT N/A
- IMMP N/A
- EPS Growth
- ADCT N/A
- IMMP N/A
- EPS
- ADCT N/A
- IMMP N/A
- Revenue
- ADCT $70,717,000.00
- IMMP $2,563,302.00
- Revenue This Year
- ADCT $6.66
- IMMP N/A
- Revenue Next Year
- ADCT $16.38
- IMMP $10.84
- P/E Ratio
- ADCT N/A
- IMMP N/A
- Revenue Growth
- ADCT N/A
- IMMP 9.59
- 52 Week Low
- ADCT $0.69
- IMMP $1.66
- 52 Week High
- ADCT $6.04
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- ADCT 25.90
- IMMP 43.26
- Support Level
- ADCT $1.89
- IMMP $1.91
- Resistance Level
- ADCT $3.06
- IMMP $2.07
- Average True Range (ATR)
- ADCT 0.23
- IMMP 0.10
- MACD
- ADCT -0.11
- IMMP 0.01
- Stochastic Oscillator
- ADCT 8.83
- IMMP 25.00
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.